$ATRC

Noznesky Justin J sold $240K of ATRC

Noznesky Justin J (Chief Mktg & Strategy Officer) sold 6,182 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.24M total) on 2026-07-29.

Original reporting
SEC EDGAR · Noznesky Justin J
Published Jul 30, 2026, 8:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATRC
Neutral
medium confidence
Mentioned
$ATRC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRCNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this specific disclosure lacks accompanying operational or financial catalysts.

02

Market read

AtriCure insider sold about $239.9K of stock; absent other news, it is more relevant for sentiment than for a fundamental repricing.

03

What to watch

No 10b5-1 plan is stated, but the filing does not explain intent, tax timing, or whether other insiders sold/bought around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-30, sale dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for AtriCure, Inc.

Company-level read

Ticker impact

$ATRCNeutralMedium confidence
Context

AtriCure Form 4 shows officer Justin J. Noznesky sold 6,182 shares at $38.80 on 2026-07-29, totaling about $239.9K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction size ($239.9K) and lack of additional context (no earnings, guidance, or operational change) reduce the probability of a durable price move.

Market effects

No clear sector read-through from a single, modest insider sale.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or personal liquidity needs and is not necessarily a bearish signal, especially without any accompanying negative corporate event.

Key entities

  • AtriCure, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Justin J. Noznesky

    Chief Mktg & Strategy Officer who sold shares.

Related articles

$ATRCHigh

AtriCure, Inc. (ATRC): Results of Operations and Financial Condition

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi